MorphoSys (MOR) Stock Price, News & Analysis

Company Overview

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Key Stats

• Today's Range: €66.70 to €67.30
• 50-Day Range: €67.25 to €67.25
• 52-Week Range: €14.52 to €69.75
• Volume: 5,144 shs
• Average Volume: 153,687 shs
• Market Capitalization: €2.53 billion
• P/E Ratio: N/A
• Dividend Yield: 1.26%
• Price Target: N/A
• Consensus Rating: N/A

MOR Stock Analysis - Frequently Asked Questions

How have MOR shares performed this year?

MorphoSys' stock was trading at €67.25 at the start of the year. Since then, MOR shares have increased by 0.0% and is now trading at €67.25.

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Novo Nordisk A/S (NVO), Bristol Myers Squibb (BMY), NVIDIA (NVDA), SolarEdge Technologies (SEDG), Gilead Sciences (GILD), AbbVie (ABBV) and Abbott Laboratories (ABT).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: ETR:MOR
• CIK: N/A
• Web: www.morphosys.de
• Phone: +49-89-899270
• Fax: N/A
• Employees: 730
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): (€12.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 322.58
• P/E Growth: 0.06
• Net Income: -€460.81 million
• Net Margins: -226.08%
• Pretax Margin: N/A
• Return on Equity: 742.62%
• Return on Assets: -13.84%

Debt

• Debt-to-Equity Ratio: -96.49
• Current Ratio: 1.38
• Quick Ratio: 3.49

Sales & Book Value

• Annual Sales: €203.82 million
• Price / Sales: 12.43
• Cash Flow: €129.73 per share
• Price / Cash Flow: 0.52
• Book Value: (€6.96) per share
• Price / Book: -9.67

Miscellaneous

• Outstanding Shares: 37,662,715
• Free Float: N/A
• Market Cap: €2.53 billion
• Optionable: Not Optionable
• Beta: 0.66